BSEBoard Meeting1d ago · 21 Jul 2026, 11:59 am
Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2026 ,inter alia, to consider and approve approve and ....
GlaxoSmithKline Pharmaceuticals Ltd · 500660
✦ AI SummaryResults
GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 03/08/2026 to consider and approve the un-audited financial results for the first quarter ended 30th June 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
GlaxoSmithKline Pharmaceuticals Ltd - 500660 - Board Meeting Intimation for Approve And Take On Record The Un-Audited Financial Results For The First Quarter Ended 30Th June 2026.
Attachments (1)
📄pdf
Download →
c0184628-9e42-46cd-8b2d-7a6a6dca65be.pdf
View document text
GlaxoSmithKline Pharmaceuticals Limited.
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com
21st July 2026
BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Dalal Street Bandra-Kurla Complex, Bandra (East)
Mumbai - 400001 Mumbai - 400051
Dear Sir,
Board Meeting
Pursuant to Regulations 29 & 33 of the Listing Obligations and Disclosure Requirements Regulations,
2015 (LODR), this is to inform you that a meeting of the Board of Directors of our Company will be
held on Monday, 3rd August 2026, inter-alia, to consider, approve and take on record the Un-audited
financial results for the first quarter ended 30th June 2026.
Kindly take the same on records.
Thanking you
Yours faithfully
For GlaxoSmithKline Pharmaceuticals Limited
Ajay Nadkarni
Vice President – Administration,
Real Estate & Company Secretary
CIN: L24239MH1924PLC001151